Given the known limitations with neurotoxic scabicides2, a recent article in the Journal of the American Academy of Dermatology highlights Spinosad 0.9% as the only prescription treatment that meets new FDA criteria for a “complete cure” of scabies based on two phase III, multi-center, randomized, double-blind, vehicle-controlled clinical trials.
A summary of the efficacy data follows:1
- As targeted topical therapy, Spinosad 0.9% represents a new scabies treatment option for physicians and patients who otherwise have few choices.
- Spinosad 0.9% has the potential to be an effective treatment for scabies due to its ability to reach mites in the stratum corneum (ie., where they feed and reproduce).
- Based on AE reporting, Spinosad 0.9% appeared well-tolerated by subjects as young as 4 years of age and did not raise safety concerns.